ARCA biopharma

ARCA's establishment is based on the belief that a precision medicine approach to drug development, which customizes medical treatment according to individual genetic characteristics of patients, can lead to more effective therapies, improved patient outcomes, and reduced healthcare costs. ARCA’s primary development programs aim to directly implement these concepts. Gencaro™ (bucindolol hydrochloride) is being developed as a potential treatment for atrial fibrillation (AF) in patients with a specific type of heart failure (HF).